Is Brilinta The Treatment To Keep AstraZeneca’s Lifeblood Flowing?
The company outlined plans to jumpstart growth of the anti-platelet drug Brilinta, including a 100% increase in marketing investment, increased rebates for payers and the addition of 200 nurse educators who will focus on the hospital discharge space.
You may also be interested in...
US President Paul Hudson talked in an interview at the J.P. Morgan Healthcare conference about the company’s budding oncology portfolio, upcoming launches and growing optimism as the 2017 return-to-growth goal approaches.
AstraZeneca’s cardiovascular drug Brilinta – one of the group’s five key growth platforms - seems to have turned the corner to give a stellar performance in the second quarter – particularly in the crucial US market.
HHS Office of Inspector General’s Mary Riordan advises drug makers to analyze their speaker programs and consulting arrangements for possible kickback activities.